What are Avalo Therapeutics's total assets?

Avalo Therapeutics (AVTX) holds $99.9M in total assets, down 27.9% year over year.

How much debt does Avalo Therapeutics have?

Avalo Therapeutics carries $328.0K in total debt against $68.3M of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Avalo Therapeutics have?

Avalo Therapeutics holds $25.3M in cash and equivalents.

Can Avalo Therapeutics cover its short-term obligations?

Its current ratio is 7.66 — current assets exceed current liabilities.

Where does Avalo Therapeutics's balance sheet data come from?

Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Avalo Therapeutics AVTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$25.32M+57.2%	$16.11M-40.9%	$27.26M-35.9%	$42.52M-66.0%	$125.24M-7.0%
Short-term investments	$57.01M-30.9%	$82.48M-2.6%	$84.65M+19.3%	$70.97M—	——
Restricted cash	$147K+297%	$37K-58.9%	$90K+350%	$20K-67.7%	$62K+226%
Prepaid expenses and other current assets	$6.69M-3.3%	$6.91M+223%	$2.14M+12.4%	$1.9M+3.8%	$1.83M-57.6%
Derivative assets	$17.52M-2.7%	$18M—	——	——	——
Total current assets	$88.83M-15.6%	$105.29M-7.5%	$113.85M-1.2%	$115.19M-9.3%	$126.94M-8.6%
Operating lease right-of-use assets	——	——	——	——	——
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%
Deferred tax assets	$446K+2.8%	$434K+42.8%	$304K+3.8%	$293K+5.4%	$278K+3.0%
Total assets	$99.89M-14.2%	$116.46M-6.9%	$125.1M-1.2%	$126.58M-8.6%	$138.52M-8.1%
Accounts payable	$356K+160%	$137K-71.1%	$474K-80.0%	$2.37M+247%	$681K+141%
Accrued expenses	$1.75M-57.6%	$4.13M+22.2%	$3.38M+57.8%	$2.14M+21.1%	$1.77M-72.0%
Operating lease liabilities, current	$328K-16.3%	$392K-10.5%	$438K-9.1%	$482K-8.4%	$526K-7.4%
Accrued interest	$500K—	——	$400K0.0%	$400K—	——
Total current liabilities	$11.6M-10.4%	$12.94M+62.3%	$7.97M-13.9%	$9.26M+64.9%	$5.62M-19.3%
Operating lease liabilities, non-current	$0-100%	$35K-70.1%	$117K-40.6%	$197K-28.4%	$275K-21.4%
Operating Lease Liabilities (Total)	$328K-23.2%	$427K-23.1%	$555K-18.3%	$679K-15.2%	$801K-12.7%
Other non-current liabilities	$0-100%	$35K-70.1%	$117K-40.6%	$197K-28.4%	$275K-21.4%
Total liabilities	$31.57M-5.5%	$33.41M-0.4%	$33.55M+52.5%	$22.01M+38.4%	$15.91M-10.1%
Common stock	200M0.0%	200M0.0%	200M0.0%	200M0.0%	200M+1,999,900%
Additional paid-in capital	$536.45M+0.9%	$531.49M+1.0%	$526.29M+3.4%	$508.77M+0.5%	$506.02M+0.5%
Retained earnings	-$468.15M-4.4%	-$448.52M-3.2%	-$434.8M-7.6%	-$404.18M-5.4%	-$383.41M-3.6%
Accumulated other comprehensive income (loss)	-$6K-109%	$68K+65.9%	$41K+221%	-$34K—	——
Total stockholders' equity	$68.32M-17.7%	$83.05M-9.3%	$91.55M-12.5%	$104.57M-14.7%	$122.62M-7.8%
Total liabilities and stockholders' equity	$99.89M-14.2%	$116.46M-6.9%	$125.1M-1.2%	$126.58M-8.6%	$138.52M-8.1%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	$0—	——	$0—	$0—	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	$0—	——	$0—	$0—	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$54.7M—	——	$18.6M-68.5%	$59.1M—	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$54.7M—	——	$18.6M-68.5%	$59.1M—	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	$0—	——	$0—	$0—	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$54.7M—	——	$18.6M-68.5%	$59.1M—	——
Cash Cash Equivalents And Short Term Investments	$82M—	——	$111.6M-1.5%	$113.3M—	——
Net Investment in Lease	$268K-20.2%	$336K-16.4%	$402K-17.5%	$487K-20.8%	$615K-17.0%
Operating lease right-of-use assets	$268K-20.2%	$336K-16.4%	$402K-17.5%	$487K-20.8%	$615K-17.0%
Property and equipment, net	$375K-18.5%	$460K-15.1%	$542K-21.0%	$686K-27.7%	$949K-21.5%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$57.01M-30.9%	$82.48M-2.6%	$84.65M+19.3%	$70.97M—	——
Operating Lease Right-of-Use Assets in Other Assets	$268K-20.2%	$336K-16.4%	$402K-17.5%	$487K-20.8%	$615K-17.0%
Accrued Manufacturing Costs	$1.75M-57.6%	$4.13M+22.2%	$3.38M+57.8%	$2.14M+21.1%	$1.77M-38.6%
Accrued Royalties (Current)	$327K0.0%	$327K0.0%	$327K0.0%	$327K0.0%	$327K-83.7%
Compensation and benefits	$1.75M-57.6%	$4.13M+22.2%	$3.38M+57.8%	$2.14M+21.1%	$1.77M-38.6%
Lease Liability Payments - 2020 (Remaining Three Months)	$282K—	——	$140K-50.0%	$280K-33.3%	$420K—
Operating Lease Liability Payments - 2024 (Lessee)	$63K—	——	$63K0.0%	$63K0.0%	$63K—
Operating Lease Liability Payments - 2025 (Lessee)	$63K—	——	$63K—	$0—	$0—
Lease Liability Payments - Remainder of Fiscal Year	$63K—	——	$392K0.0%	$392K0.0%	$392K—
Operating Lease Liability Payments Due	$345K—	——	$595K-19.0%	$735K-16.0%	$875K—
Operating Lease Liability - Undiscounted Excess Amount	$17K—	——	$40K-28.6%	$56K-24.3%	$74K—
Derivative Liabilities (Non-Current)	$17.52M-2.7%	$18M-22.3%	$23.16M+126%	$10.26M+32.6%	$7.74M-4.7%
Accrued expenses and other liabilities	$11.24M-12.2%	$12.8M+70.8%	$7.5M+14.9%	$6.52M+42.6%	$4.57M-27.6%
Total debt	$328K-23.2%	$427K-23.1%	$555K-18.3%	$679K-15.2%	$801K-12.7%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$0—	——	$0—	$0—	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	24.6M+33.1%	18.5M+3.8%	17.8M+64.5%	10.8M+0.1%	10.8M+3.4%
Common Stock Shares Outstanding	$23.8M-40.4%	$39.9M—	——	——	——
Convertible Preferred Stock Authorized Shares	5M—	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$25K+38.9%	$18K0.0%	$18K+63.6%	$11K0.0%	$11K+10.0%
Number of Exercisable Options	$7.5M—	——	——	——	——
Preferred Stock Par Value Per Share	$0.00—	——	——	——	——
Temporary Equity Attributable to Parent	$0—	$0—	$0—	$0—	$0—
Fair Value Measurement Disclosure	$17.52M-2.7%	$18M—	——	——	$8.1M-4.5%
Gross Assets/Liabilities	$17.52M-2.7%	$18M—	——	——	——
General and administrative	$889K+30.4%	$682K—	——	——	——
Research and development	$7.95M+9.3%	$7.27M—	——	——	——
Licensing Arrangements	$327K0.0%	$327K0.0%	$327K0.0%	$327K0.0%	$327K0.0%
Accrued Royalties	$2M0.0%	$2M0.0%	$2M0.0%	$2M0.0%	$2M0.0%
Number of shares of capital stock authorized to issue (in shares)	205M—	——	205M0.0%	205M0.0%	205M—
Cash, Cash Equivalents And Debt Securities, Available-For-Sale, Excluding Accrued Interest	$69.34M-24.3%	$91.55M—	——	——	——
Amortized Cost	$69.34M—	——	——	——	——
Cash, Cash Equivalents And Debt Securities, Available-For-Sale, Unrealized Losses Excluding Accrued Interest	$18K—	——	——	——	——
Unrealized Gains	$11K—	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$24.64M+33.1%	$18.51M+3.8%	$17.83M+64.5%	$10.84M+0.1%	$10.83M+3.4%
Common Stock, Shares, Outstanding	$24.64M+33.1%	$18.51M+3.8%	$17.83M+64.5%	$10.84M+0.1%	$10.83M+3.4%
Less than 12 months	$54.7M—	——	$18.6M-68.5%	$59.1M—	——
12 months or more	$0—	——	$0—	$0—	——
Deferred income taxes	$446K+2.8%	$434K+42.8%	$304K+3.8%	$293K+5.4%	$278K+3.0%
Derivative Liability	$17.52M-2.7%	$18M—	——	——	——
Derivative Liability, Noncurrent	$17.52M-2.7%	$18M-22.3%	$23.16M+126%	$10.26M+32.6%	$7.74M-4.7%
Lessee Operating Lease Discount Rate	$0.11—	——	$0.1+3.1%	$0.1+1.0%	$0.1—
Lessee Operating Lease Liability Payments Due	$345K—	——	$595K-19.0%	$735K-16.0%	$875K—
Lessee Operating Lease Liability Undiscounted Excess Amount	$17K—	——	$40K-28.6%	$56K-24.3%	$74K—
Number of classes of stock authorized to issue	2—	——	20.0%	20.0%	2—
Preferred Stock, Par or Stated Value Per Share	$0—	——	——	——	——
Preferred Stock, Shares Authorized	$5M—	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	$7.5M—	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$23.8M-40.4%	$39.9M—	——	——	——
Temporary Equity Shares Outstanding	20.0%	20.0%	20.0%	20.0%	20.0%
Remainder of Fiscal Year 2024	$282K—	——	$140K-50.0%	$280K-33.3%	$420K—
Weighted-Average Discount Rate	10.5%—	——	10%+0.3%	9.7%+0.1%	9.6%—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Avalo Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Avalo Therapeutics's total assets?: Avalo Therapeutics (AVTX) holds $99.9M in total assets, down 27.9% year over year.
How much debt does Avalo Therapeutics have?: Avalo Therapeutics carries $328.0K in total debt against $68.3M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Avalo Therapeutics have?: Avalo Therapeutics holds $25.3M in cash and equivalents.
Can Avalo Therapeutics cover its short-term obligations?: Its current ratio is 7.66 — current assets exceed current liabilities.
Where does Avalo Therapeutics's balance sheet data come from?: Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.